UK Markets closed
NIKKEI 225
27,346.88 +19.77 (+0.07%) HANG SENG
22,072.18 +229.85 (+1.05%) CRUDE OIL
77.08 -1.79 (-2.27%) GOLD FUTURES
1,967.10 +21.80 (+1.12%) DOW
34,251.01 +164.97 (+0.48%) BTC-GBP
19,048.70 +315.46 (+1.68%)
Sarepta Therapeutics, Inc. (0L35.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 06:54PM GMT
| Previous close | 124.82 |
| Open | 119.88 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 119.88 - 119.88 |
| 52-week range | 119.88 - 119.88 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 9.761B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
SOMERSET, N.J. & CAMBRIDGE, Mass., January 05, 2023--Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dy
© 2023 Yahoo. All rights reserved.
